An investigational triple agonist adding glucagon-receptor activity to the GIP/GLP-1 mechanism. Trial results to date report the largest average weight reduction of the class, but it is not approved and is not legally available.
Investigational — in Phase 3 trials, not approved. Compounds in this category have not been approved for human use; availability is typically restricted to laboratory research.
Ranges compiled from published protocols, not a clinical guideline. Convert a dose into syringe units with the dosage calculator.
This page summarises how much a compound has been studied. A high publication count is not evidence that something works, is safe, or is legal to obtain where you live. Consult a qualified healthcare provider before acting on anything here.
Our mission is to make peptide research clear, credible, and usable for people who refuse to rely on hype.